Agenus Inc. (NASDAQ:AGEN) Receives Average Rating of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have earned a consensus rating of “Hold” from the six analysts that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.00.

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th.

Institutional Investors Weigh In On Agenus

Several large investors have recently made changes to their positions in AGEN. Federated Hermes Inc. acquired a new position in Agenus in the 2nd quarter worth $1,921,000. Blair William & Co. IL bought a new stake in shares of Agenus in the second quarter valued at about $441,000. Point72 DIFC Ltd acquired a new position in shares of Agenus during the second quarter worth about $51,000. Squarepoint Ops LLC bought a new position in shares of Agenus during the second quarter worth about $614,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Agenus in the 2nd quarter valued at approximately $106,000. Institutional investors own 61.46% of the company’s stock.

Agenus Stock Performance

Shares of NASDAQ:AGEN opened at $3.14 on Friday. The company has a 50 day moving average price of $3.18 and a two-hundred day moving average price of $5.55. The company has a market capitalization of $73.66 million, a PE ratio of -0.28 and a beta of 1.27. Agenus has a 52 week low of $2.50 and a 52 week high of $19.69.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.